-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
-
Summary
-
Iovance Biotherapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2010 to 2023.
- Iovance Biotherapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending June 30, 2024 was -$97.1M, a 8.85% increase year-over-year.
- Iovance Biotherapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending June 30, 2024 was -$440M, a 5.11% decline year-over-year.
- Iovance Biotherapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$444M, a 12.2% decline from 2022.
- Iovance Biotherapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$396M, a 15.7% decline from 2021.
- Iovance Biotherapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$342M, a 31.8% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Growth (%)